Mineralys Therapeutics, Inc. Common Stock

MLYSNASDAQ • USD
14.72 USD
↘ 0.61 (3.98%)🟢LIVE (AS OF 02:00 PM EST)
🟢Market: OPEN

Shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) are trading at $14.72. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 13, 2026.

Open?$15.16
High?$15.55
Low?$14.72
Prev. Close?$15.33
Volume?334.8K
Avg. Volume?1.8M
VWAP?$15.03
Rel. Volume?0.18x
Bid / Ask
Bid?$14.75 × 100
Ask?$14.83 × 100
Spread?$0.08
Midpoint?$14.79
Valuation & Ratios
Market Cap?1.4B
Shares Out?88.6M
Float?63.9M
Float %?72.3%
P/E Ratio?N/A
P/B Ratio?2.69
EPS?-$4.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Employees
76
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-02-10
Address
150 N. RADNOR CHESTER ROAD
RADNOR, PA
Phone: (888) 378-6240
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
88
Momentum?
50
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?3.73Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.03%High
Short Interest?7.7M
Days to Cover?5.0
Free Float63.9M
Avg Daily Volume1.6M
Settlement Date2026-10-30
Financial Health
Current Ratio?11.83Strong
Quick Ratio?11.83Strong
Cash Ratio?1.91Strong
Debt/Equity?0.20Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
61
2.69CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-73.4%WEAK▾
ROA?
S&P
3
-58.7%WEAK▾
Cash Flow & Enterprise
FCF?$-153026000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day